Tirzepatide vs Semaglutide
The two most-discussed metabolic compounds: a dual GIP/GLP-1 agonist versus a GLP-1 agonist.
Tirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Semaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~5 days | ~7 days |
| Molecular weight | 4,813.5 Da | 4,113.6 Da |
| Mechanism | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Legal status (US) | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Tirzepatide or Semaglutide?
Tirzepatide is rated Strong and Semaglutide is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Tirzepatide and Semaglutide FDA-approved?
Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.